Abstract:The complement system is an innate immune defense cascade that can cause tissue damage when inappropriately activated. Evidence for complement overactivation has been reported in small cohorts of patients with sickle cell disease (SCD). However, the mechanism governing complement activation in SCD has not been elucidated. Here, we observe that the plasma concentration of sC5b‐9, a reliable marker for terminal complement activation, is increased at steady state in 61% of untreated SCD patients. We show that greater complement activation in vitro is promoted by SCD erythrocytes compared to normal ones, although no significant differences were observed in the regulatory proteins CD35, CD55, and CD59 in whole blood. Complement activation is positively correlated with the percentage of dense sickle cells (DRBCs). The expression levels of CD35, CD55, and CD59 are reduced in DRBCs, suggesting inefficient regulation when cell density increases. Moreover, the surface expression of the complement regulator CD46 on granulocytes was inversely correlated with the plasma sC5b‐9. We also show increased complement deposition in cultured human endothelial cells incubated with SCD serum, which is diminished by the addition of the heme scavenger hemopexin. Treatment of SCD patients with hydroxyurea produces substantial reductions in complement activation, measured by sC5b‐9 concentration and upregulation of CD46, as well as decreased complement activation on RBCs in vitro. In conclusion, complement overactivation is a common pathogenic event in SCD that is associated with formation of DRBCs and hemolysis and affects red cells, leukocytes and endothelial cells. This complement overactivation is partly alleviated by hydroxyurea therapy.This article is protected by copyright. All rights reserved.

Vascular pathophysiology of sickle cell disease

Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction

Sickle cell disease as a vascular disorder

Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness

Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism

Biomechanics and biorheology of red blood cells in sickle cell anemia

[Hemostasis alterations in sickle cell syndrome]

Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications

[Pulmonary complications in adult sickle cell disease]

End Organ Affection in Sickle Cell Disease

Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease

Sickle Cell Disease: From Genetics to Curative Approaches

Management of Acute Complications of Sickle Cell Disease

Controversies in the pathophysiology of leg ulcers in sickle cell disease

Heme- and iron-activated macrophages in sickle cell disease: an updated perspective

Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

A Review of the Relationship between the Immune Response, Inflammation, Oxidative Stress, and the Pathogenesis of Sickle Cell Anaemia

Exercise and training in sickle cell disease: Safety, potential benefits, and recommendations

The clinical spectrum of HbSC sickle cell disease‐not a benign condition